特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
921872

世界の自己免疫疾患治療市場:成長、動向、および予測(2020年~2025年)

Autoimmune Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 114 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
世界の自己免疫疾患治療市場:成長、動向、および予測(2020年~2025年)
出版日: 2020年06月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 114 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界の自己免疫疾患治療市場は、予測期間中に4.2%のCAGRで成長すると見通しです。同市場の主な成長要因には、自己免疫疾患の有病率の急増が挙げられます。自己免疫疾患治療薬の研究開発への投資の増加、診断の技術的進歩、治療の認識などは、自己免疫治療市場を次のレベルに引き上げる上で重要な役割を果たす要因です。ただし、治療薬の高いコスト、医療保険の適用範囲の狭さは、同市場の成長を妨げています。

当レポートは自己免疫疾患治療市場について調査しており、市場機会や動向、成長および阻害要因、適応症・薬剤クラス・販売チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概況
  • 市場成長要因
    • 自己免疫疾患の有病率の上昇
    • 研究開発への投資の増加
    • 診断方法の進歩
  • 市場阻害要因
    • 治療費の増加
    • 自己免疫疾患の低医療保険適用範囲
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 適応症別
    • リウマチ性疾患
    • 糖尿病
    • 多発性硬化症
    • 炎症性腸疾患
    • その他
  • 薬剤クラス別
    • 抗炎症剤
    • 血糖降下薬
    • NSAID
    • インターフェロン
    • その他
  • 販売チャネル別
    • 病院薬局
    • オンライン
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Abbvie
    • Amgen Inc.
    • Johnson & Johnson
    • Eli Lilly and Company
    • Pfizer Inc.
    • F. Hoffmann-La Roche AG
    • Astrazeneca Plc
    • Bristol-Myers Squibb Co.
    • Lupin Limited
    • GlaxoSmithKline Plc

第7章 市場機会および今後の動向

目次
Product Code: 67371

The autoimmune treatment market is expected to grow with a CAGR of 4.2%, over the forecast period. The major factor attributing to the growth of the autoimmune treatment market is surge in prevalence of autoimmune diseases. According to NIH (National Institutes of Health) up to 23.5 million Americans have an autoimmune disease and the prevalance is increasing. Scientists have identified 80-100 various autoimmune diseases and assume at least 40 other diseases of having an autoimmune basis. The other factors that play a major role in taking the autoimmune treatment market to the next level are increasing investments in research and development of drugs for autoimmune diseases, technological advancements in diagnosis and awareness of the therapy. Rising government initiatives for regulating these diseases is also helping the growth of the market. However, higher costs of the therapeutics and low medical insurance coverage are constraining the market growth.

Key Market Trends

Rheumatic Disease segment is Expected to Hold Large Market Share

  • The rheumatic disease segment is expected to dominate the market owing to the rising cases of diseases. Rheumatic diseases are described by swelling that affects the connecting structures of the body, mostly the joints, sometimes the tendons, ligaments, bones, and muscles.
  • The therapeutics for rheumatoid disease holds the significant share and expected to remain assertive during the forecast period, due to the rising geriatric population, increasing number of pipeline drugs and the increasing cases of arthritis, fibromyalgia, systemic lupus erythematosus, gout and others, and varied range and availability of progressive therapeutics for the treatment of these diseases.
  • In 2018, according to RheumatoidArthritis.org, around 1.3 million Americans were affected by Rheumatoid arthritis, and the number is increasing every year, which is a driving factor for the autoimmune treatment market.

North America Dominates the Market and Expected to do same in the Forecast Period

North America is expected to dominate the overall autoimmune treatment market, throughout the forecast period. This is due to factors such as the rising incidence and prevalence of autoimmune diseases like arthritis, lupus, multiple sclerosis, in the country. In the North America region, the United States holds the largest market share due to growing personal expenditure on healthcare. The healthcare commerce in the province is developing at a quick stride, resulting in the progress of the North America Autoimmune treatment market. Furthermore, beneficial government initiatives and an increase in the number of research partnerships are some of the drivers expected to increase market growth.

Competitive Landscape

The autoimmune treatment market is moderately competitive and consists of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are AbbVie, Amgen, Johnson & Johnson, Eli Lilly & Co., Pfizer, F. Hoffmann-La Roche AG, Astrazeneca Plc and Bristol-Myers Squibb Co.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in the Prevalence of Autoimmune Diseases
    • 4.2.2 Increasing Investments in Research and development
    • 4.2.3 Advancements in Diagnostic Methods
  • 4.3 Market Restraints
    • 4.3.1 Higher Cost of Therapeutics
    • 4.3.2 Low Medical Insurance Coverage for Autoimmune Diseases
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Indication
    • 5.1.1 Rheumatic Disease
    • 5.1.2 Diabetes
    • 5.1.3 Multiple Sclerosis
    • 5.1.4 Inflammatory Bowel Disease
    • 5.1.5 Other Indications
  • 5.2 By Drug Class
    • 5.2.1 Anti-Inflammatory
    • 5.2.2 Anti-Hyperglycemics
    • 5.2.3 NSAIDs
    • 5.2.4 Interferons
    • 5.2.5 Other Drugs
  • 5.3 By Sales Channel
    • 5.3.1 Hospital Pharmacy
    • 5.3.2 Online
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle-East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle-East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbvie
    • 6.1.2 Amgen Inc.
    • 6.1.3 Johnson & Johnson
    • 6.1.4 Eli Lilly and Company
    • 6.1.5 Pfizer Inc.
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 Astrazeneca Plc
    • 6.1.8 Bristol-Myers Squibb Co.
    • 6.1.9 Lupin Limited
    • 6.1.10 GlaxoSmithKline Plc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.